search

Nurix Therapeutics Inc (NRIX)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Nurix Therapeutics (NASDAQ:NRIX) Upgraded to "Hold" at Wall Street Zen
Sep 26, 2026

Nurix Therapeutics (NASDAQ:NRIX) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen has upgraded Nurix Therapeutics (NASDAQ:NRIX) from "Sell" to "Hold," though the broader analyst consensus remains a "Moderate Buy" with an average price target of $34.21. This upgrade follows a period where the company's shares opened down 2.7%, and its latest quarterly results missed expectations, reporting an adjusted loss of $0.81 per share and revenue of $9.04 million. Despite insider stock sales totaling over $500,000 in the last three months, several institutional investors have initiated new positions in the company.
Company relevance
100.00%
Company sentiment
Neutral
Overall sentiment
Somewhat-Bullish